BACKGROUND: The impact of recent medical advances on disease presentation, extent of operation, and disease-specific survival for patients with medullary thyroid cancer is unclear. METHODS: We used the Surveillance, Epidemiology, and End Results registry to compare trends over 3 time periods, 1983-1992, 1993-2002, and 2003-2012. RESULTS: There were 2,940 patients diagnosed with medullary thyroid cancer between 1983 and 2012. The incidence of medullary thyroid cancer increased during this time period from 0.14 to 0.21 per 100,000 population, and mean age at diagnosis increased from 49.8 to 53.8 (P < .001). The proportion of tumors ≤1 cm also increased from 11.4% in 1983-1992, 19.6% in 1993-2002, to 25.1% in 2003-2012 (P < .001), but stage at diagnosis remained constant (P = .57). In addition, the proportion of patients undergoing a total thyroidectomy and lymph node dissection increased from 58.2% to 76.5% during the study period (P < .001). In the most recent time interval, 5-year, disease-specific survival improved from 86% to 89% in all patients (P < .001) but especially for patients with regional (82% to 91%, P = .003) and distant (40% to 51%, P = .02) disease. CONCLUSION: These data demonstrate that the extent of operation is increasing for patients with medullary thyroid cancer. Disease-specific survival is also improving, primarily in patients with regional and distant disease.
BACKGROUND: The impact of recent medical advances on disease presentation, extent of operation, and disease-specific survival for patients with medullary thyroid cancer is unclear. METHODS: We used the Surveillance, Epidemiology, and End Results registry to compare trends over 3 time periods, 1983-1992, 1993-2002, and 2003-2012. RESULTS: There were 2,940 patients diagnosed with medullary thyroid cancer between 1983 and 2012. The incidence of medullary thyroid cancer increased during this time period from 0.14 to 0.21 per 100,000 population, and mean age at diagnosis increased from 49.8 to 53.8 (P < .001). The proportion of tumors ≤1 cm also increased from 11.4% in 1983-1992, 19.6% in 1993-2002, to 25.1% in 2003-2012 (P < .001), but stage at diagnosis remained constant (P = .57). In addition, the proportion of patients undergoing a total thyroidectomy and lymph node dissection increased from 58.2% to 76.5% during the study period (P < .001). In the most recent time interval, 5-year, disease-specific survival improved from 86% to 89% in all patients (P < .001) but especially for patients with regional (82% to 91%, P = .003) and distant (40% to 51%, P = .02) disease. CONCLUSION: These data demonstrate that the extent of operation is increasing for patients with medullary thyroid cancer. Disease-specific survival is also improving, primarily in patients with regional and distant disease.
Authors: Emad Kandil; Marta M Gilson; Haytham H Alabbas; Anthony P Tufaro; Alan Dackiw; Ralph P Tufano Journal: Ann Surg Oncol Date: 2010-10-29 Impact factor: 5.344
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman Journal: J Clin Oncol Date: 2013-09-03 Impact factor: 44.544
Authors: Louise Davies; Luc G T Morris; Megan Haymart; Amy Y Chen; David Goldenberg; John Morris; Jennifer B Ogilvie; David J Terris; James Netterville; Richard J Wong; Gregory Randolph Journal: Endocr Pract Date: 2015-06 Impact factor: 3.443
Authors: Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: Garth F Essig; Kyle Porter; David Schneider; Arpaia Debora; Susan C Lindsey; Giulia Busonero; Daniel Fineberg; Barbara Fruci; Kristien Boelaert; Johannes W Smit; Johannes Arnoldus Anthonius Meijer; Leonidas Duntas; Neil Sharma; Giuseppe Costante; Sebastiano Filetti; Rebecca S Sippel; Bernadette Biondi; Duncan J Topliss; Furio Pacini; Rui M B Maciel; Patrick C Walz; Richard T Kloos Journal: Endocr Pract Date: 2013 Nov-Dec Impact factor: 3.443
Authors: Else Marie Opsahl; Lars Andreas Akslen; Ellen Schlichting; Turid Aas; Katrin Brauckhoff; Anne Irene Hagen; Alf Frimann Rosenlund; Eva Sigstad; Krystyna K Grøholt; Lars H Jørgensen; Trine Bjøro Journal: Eur Thyroid J Date: 2019-04-29
Authors: Else Marie Opsahl; Lars Andreas Akslen; Ellen Schlichting; Turid Aas; Katrin Brauckhoff; Anne Irene Hagen; Alf Frimann Rosenlund; Eva Sigstad; Krystyna K Grøholt; Lovise Mæhle; Lars Fredrik Engebretsen; Lars H Jørgensen; Jan Erik Varhaug; Trine Bjøro Journal: Eur Thyroid J Date: 2018-11-08